Loading
Life sciences · Journal article
Applied Biosciences · September 23, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Obesity is a global health threat, which continues to rise in prevalence worldwide, driving increases in related chronic diseases such as type 2 diabetes and cardiovascular conditions. While the sheer scale of the crisis affects over a billion people worldwide, the challenge is compounded for a distinct population: patients with genetically inherent obesity. Gene therapy targeting adipose tissue offers promise for treating obesity, but it requires development of tissue-targeting methods to minimize off-target effects and ensure safety. Our study presents two strategies to restrict transgene expression specifically to adipocytes: engineered adipose-specific promoters and optogenetic regulation. We designed truncated promoter fragments from murine Ucp1, Adipoq, and Fabp4 genes and evaluated their activity during 3T3-L1 preadipocyte differentiation. While all adipocyte-specific promoters exhibited substantially lower activity than the constitutive Cytomegalovirus promoter (10- to 100-fold reduction), they displayed distinct temporal activation patterns: Ucp1 peaked during active differentiation, whereas Adipoq was predominantly active in mature adipocytes. In vivo validation using AAV6/8 vectors confirmed adipose expression of the fluorescent reporter Katushka2S under the Ucp1 promoter in murine interscapular fat. Bioinformatic analysis (MAST/MCAST) of six adipocyte-enriched genes (Fabp4, Adipoq, Ucp1, Lep, Cidec, Sfrp5) identified high-density transcription factor binding site clusters that can be used for the development of new promoters for adipose-specific expression. Furthermore, we implemented the iLight optogenetic system to achieve light-dependent reassembly of split FOXP4 and PRDM16 transcription factors, demonstrating tunable Ucp1 activation with minimal basal expression. These strategies—development of synthetic adipose-specific mini-promoters and light-inducible regulation—may serve as a basis for developing precision metabolic medicine as these approaches allow spatiotemporal control of transgene expression.